Sickest cancer patients may get electroporation:
This article was originally published in Clinica
Genetronics Biomedical has asked the FDA to grant it permission to use its experimental drug delivery technology on patients with aggressive skin, head and neck cancers. The San Diego, California-based company has filed a compassionate use protocol with the agency which would allow it to test its electroporation therapy technique, which uses electric currents to deliver cancer drugs, on patients who have failed standard drug treatment and are not able to, or do not want to, undergo surgery, radiation therapy or additional chemotherapy.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.